Pancreatic Cancer Serum and DNA Repository

Sponsor
Pancreatic Cancer Research Team (Other)
Overall Status
Completed
CT.gov ID
NCT00296114
Collaborator
(none)
690
10
94
69
0.7

Study Details

Study Description

Brief Summary

To prospectively collect serum and DNA samples from subjects with pancreatic cancer, pancreatitis, liver disease, and from healthy and at-risk volunteers in order to identify novel biomarkers for early diagnosis, differential diagnosis, stage, natural history of the disease, response to treatment, and to identify novel targets for therapeutic interventions.

In particular:
Condition or Disease Intervention/Treatment Phase
  • Procedure: Serum and DNA Samples

Detailed Description

  • To establish a central pancreatic cancer specimen repository to serve as a resource for current and future scientific studies.

  • To utilize the PCRT clinical data base to perform clinicopathologic correlation with the results of those studies.

  • To test new hypotheses as they emerge.

Study Design

Study Type:
Observational
Actual Enrollment :
690 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Pancreatic Cancer Serum and DNA Repository
Study Start Date :
Feb 1, 2004
Actual Primary Completion Date :
Dec 1, 2011
Actual Study Completion Date :
Dec 1, 2011

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

    Criteria

    Inclusion Criteria:

    4.1 At the time of subject registration, CRAB will verify the institution's IRB date to ensure that the subject can be enrolled.

    4.2 Potential study participants must meet the eligibility criteria found in Section 12.0 (Eligibility Checklist). Candidates will fall into one of four groups:

    1. Pancreatic cancer patients;

    2. Pancreatic and Liver Disease patients;

    3. Healthy, At-Risk Volunteers (smoker, (defined as individuals who have smoked >= 100 cigarettes in their lifetime, and who currently smoke every day or some days [MMWR November 12, 2004, 53(44);1035-1037]), diabetic, and/or family history); and

    4. Healthy Volunteers (no history of cancer). The Eligibility Checklist must be photocopied, completed and stored on site. Eligibility is confirmed during registration, by answering yes to the question, Have all eligibility criteria been met? on the Registration Form.

    Eligibility Checklist:
    1. Pancreatic Cancer Patient Criteria All subjects, regardless of gender and ethnicity are eligible for this study Pathological diagnosis of pancreatic malignant neoplasm Expected availability of clinical follow up data Eighteen years old or older All subjects must be informed of the investigational nature of this protocol Written, informed consent obtained in accordance with institutional and federal guidelines

    2. Pancreatitis and Liver Disease Subject Criteria All subjects, regardless of gender and ethnicity are eligible for this study Pathological diagnosis of pancreatitis or liver disease Eighteen years old or older All subjects must be informed of the investigational nature of this protocol Written, informed consent obtained in accordance with institutional and federal guidelines

    3. Healthy, At-Risk Volunteers All subjects, regardless of gender and ethnicity are eligible for this study Is a smoker, is diabetic AND/OR has a family history of pancreatic cancer Eighteen years old or older with no history of cancer All subjects must be informed of the investigational nature of this protocol Written, informed consent obtained in accordance with institutional and federal guidelines

    4. Healthy Volunteers (no at-risk factors) All subjects, regardless of gender and ethnicity are eligible for this study Eighteen years old or older with no history of cancer All subjects must be informed of the investigational nature of this protocol Written, informed consent obtained in accordance with institutional and federal guidelines

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Scottsdale Healthcare Scottsdale Arizona United States 85259
    2 University of Arizona/Arizona Cancer Center Tucson Arizona United States 85724
    3 UCLA Medical Center Los Angeles California United States 90024-6970
    4 RUSH University Medical Center Chicago Illinois United States 60612
    5 Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Baltimore Maryland United States 21231
    6 Abbott Northwestern Hospital/Virginia Piper Cancer Institute Minneapolis Minnesota United States 55407
    7 University of New Mexico Albuquerque New Mexico United States 87131
    8 Sarah Cannon Research Institute Nashville Tennessee United States 37203
    9 South Texas Oncology and Hematology San Antonio Texas United States 78229
    10 University Hospital (12 De Octubre) Madrid Spain

    Sponsors and Collaborators

    • Pancreatic Cancer Research Team

    Investigators

    • Study Chair: Manuel Hidalgo, MD, PhD, Hospital Universitario Sanchinarro, Madrid, Spain

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Pancreatic Cancer Research Team
    ClinicalTrials.gov Identifier:
    NCT00296114
    Other Study ID Numbers:
    • PCRT 03 001
    • NCT00250107
    First Posted:
    Feb 24, 2006
    Last Update Posted:
    May 1, 2013
    Last Verified:
    Dec 1, 2011
    Keywords provided by Pancreatic Cancer Research Team
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 1, 2013